GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Idorsia Ltd (XSWX:IDIA) » Definitions » EV-to-EBIT

Idorsia (XSWX:IDIA) EV-to-EBIT : -3.81 (As of May. 27, 2024)


View and export this data going back to 2017. Start your Free Trial

What is Idorsia EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Idorsia's Enterprise Value is CHF1,324.4 Mil. Idorsia's EBIT for the trailing twelve months (TTM) ended in Sep. 2023 was CHF-347.5 Mil. Therefore, Idorsia's EV-to-EBIT for today is -3.81.

The historical rank and industry rank for Idorsia's EV-to-EBIT or its related term are showing as below:

XSWX:IDIA' s EV-to-EBIT Range Over the Past 10 Years
Min: -394.62   Med: -6.1   Max: 100.23
Current: -3.81

During the past 7 years, the highest EV-to-EBIT of Idorsia was 100.23. The lowest was -394.62. And the median was -6.10.

XSWX:IDIA's EV-to-EBIT is ranked worse than
100% of 424 companies
in the Biotechnology industry
Industry Median: 10 vs XSWX:IDIA: -3.81

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Idorsia's Enterprise Value for the quarter that ended in Sep. 2023 was CHF1,401.7 Mil. Idorsia's EBIT for the trailing twelve months (TTM) ended in Sep. 2023 was CHF-347.5 Mil. Idorsia's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2023 was -24.79%.


Idorsia EV-to-EBIT Historical Data

The historical data trend for Idorsia's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Idorsia EV-to-EBIT Chart

Idorsia Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
EV-to-EBIT
Get a 7-Day Free Trial -4.76 -7.99 -8.82 -5.64 -3.90

Idorsia Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3.27 -3.90 -3.41 -2.98 -4.03

Competitive Comparison of Idorsia's EV-to-EBIT

For the Biotechnology subindustry, Idorsia's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Idorsia's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Idorsia's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Idorsia's EV-to-EBIT falls into.



Idorsia EV-to-EBIT Calculation

Idorsia's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=1324.445/-347.504
=-3.81

Idorsia's current Enterprise Value is CHF1,324.4 Mil.
Idorsia's EBIT for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was CHF-347.5 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Idorsia  (XSWX:IDIA) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Idorsia's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Sep. 2023 ) =EBIT / Enterprise Value (Q: Sep. 2023 )
=-347.504/1401.69584
=-24.79 %

Idorsia's Enterprise Value for the quarter that ended in Sep. 2023 was CHF1,401.7 Mil.
Idorsia's EBIT for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was CHF-347.5 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Idorsia EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Idorsia's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Idorsia (XSWX:IDIA) Business Description

Traded in Other Exchanges
Address
Hegenheimermattweg 91, Allschwil, CHE, 4123
Idorsia Ltd is a biopharmaceutical company engaged in discovering, developing, and commercializing of medicines for unmet medical needs. It is a biotech hub of Europe specialized in the discovery and development of small molecules, to provide innovative therapeutic options. The company focuses on multiple therapeutic areas which include the central nervous system, cardiovascular disorders, immunological disorders, and orphan diseases. Idorsia's development compounds target a number of different diseases such as Resistant Hypertension, lupus, insomnia, Cerebral vasospasm, and Fabry disease. Geographically, it derives revenue from Switzerland.

Idorsia (XSWX:IDIA) Headlines

No Headlines